Comparison of Changes in Bone Density and Turnover with Abacavir‐Lamivudine versus Tenofovir‐Emtricitabine in HIV‐Infected Adults: 48‐Week Results from the ASSERT Study
2010; Oxford University Press; Volume: 51; Issue: 8 Linguagem: Inglês
10.1086/656417
ISSN1537-6591
AutoresHans‐Jürgen Stellbrink, Chloe Orkin, José Ramón Arribas, Juliet Compston, Jan Gerstoft, Eric Van Wijngaerden, Adriano Lazzarin, Giuliano Rizzardini, Herman G. Sprenger, John S. Lambert, Gunta Stūre, David Leather, Sara Hughes, Patrizia Zucchi, Helen Pearce,
Tópico(s)HIV Research and Treatment
ResumoBackground. Abacavir-lamivudine and tenofovir DF-emtricitabine fixed-dose combinations are commonly used as first-line antiretroviral therapies. However, few studies have comprehensively compared their relative safety profiles.
Referência(s)